REFERENCES:
[1] Barrett, J.S., Bishai, R., Bucci‐Rechtweg, C., Cheung, A.,
Corriol‐Rohou, S., Haertter, S., James, A., Kovacs, S.J., Liu, J.,
Potempa, D., Strougo, A., Vanevski, K. and (2018), Challenges and
Opportunities in the Development of Medical Therapies for Pediatric
Populations and the Role of Extrapolation. Clin. Pharmacol. Ther., 103:
419-433. doi:10.1002/cpt.1000
[2] Zimmermann P, Curtis N. Coronavirus Infections in Children
Including COVID-19, The Pediatric Infectious Disease Journal: May 2020.
39(5): 355-368. doi: 10.1097/INF.0000000000002660
[3] Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S,
Gallagher T. A Transmembrane Serine Protease Is Linked to the Severe
Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus
Entry. Journal of Virology 85(2): 873–882, 2011,
doi:10.1128/JVI.02062-10.
[4] Hoffmann M et al., SARS-CoV-2 Cell Entry Depends on ACE2 and
TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 2020,
Cell 181(2): 271–280, https://doi.org/10.1016/j.cell.2020.02.052.
[5] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of
Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
[6] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan,
China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med
2020;382:1199-207.
[7] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
[8] Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet
2020;395:497-506.
[9] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China. JAMA 2020.
[10] Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of
patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside
of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
[11] Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute
Respiratory Distress Syndrome and Death in Patients With Coronavirus
Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
[12] Pan L, Mu M, Yang P, et al. Clinical Characteristics of
COVID-19 Patients with Digestive Symptoms in Hubei, China: A
Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol
2020.
[13] Ludvigsson JF. Systematic review of COVID-19 in children shows
milder cases and a better prognosis than adults. Acta Paediatr.
2020;109(6):1088‐1095. doi:10.1111/apa.15270
[14] Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among
Children in China. Pediatrics. 2020;145(6):e20200702.
doi:10.1542/peds.2020-0702
[15] Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, Li P, Zhou
Y, Lin YF, Duan Q, Luo G, Fan S, Lu Y, Feng A, Zhan Y, Liang B, Cai W,
Zhang L, Du X, Li L, Shu Y, Zou H. Clinical characteristics of
coronavirus disease 2019 (COVID-19) in China: A systematic review and
meta-analysis. J Infect. 2020 Jun;80(6):656-665. doi:
10.1016/j.jinf.2020.03.041. Epub 2020 Apr 10. PMID: 32283155; PMCID:
PMC7151416.
[16] Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and
COVID-19: The most important research questions. Cell Biosci. 2020 Mar
16;10:40. doi: 10.1186/s13578-020-00404-4. PMID: 32190290; PMCID:
PMC7074995.
[17] Hasan A, Mehmood N, Fergie J (March 31, 2020) Coronavirus
Disease (COVID-19) and Pediatric Patients: A Review of Epidemiology,
Symptomatology, Laboratory and Imaging Results to Guide the Development
of a Management Algorithm. Cureus 12(3): e7485. doi:10.7759/cureus.7485
[18] Siddiqi HK, Mehra MR. COVID-19 illness in native and
immunosuppressed states: A clinical-therapeutic staging proposal. J
Heart Lung Transplant. 2020;39(5):405‐407,
doi:10.1016/j.healun.2020.03.012
[19] Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A.
Physiological changes in pregnancy. Cardiovasc J Afr. 2016
Mar-Apr;27(2):89-94. doi: 10.5830/CVJA-2016-021. PMID: 27213856; PMCID:
PMC4928162.
[20] Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of
drugs in pregnancy. Semin Perinatol. 2015 Nov;39(7):512-9. doi:
10.1053/j.semperi.2015.08.003. PMID: 26452316; PMCID: PMC4809631.
[21] Guidance for Industry: Pediatric Information Incorporated into
Human Prescription Drug and Biological Product Labeling. U.S. Department
of Health and Human Services Food and Drug Administration, Center for
Drug Evaluation and Research (CDER), Center for Biologics Evaluation and
Research (CBER), March 2019, https://www.fda.gov/media/84949/download
[22] Guidance for Industry: General Clinical Pharmacology
Considerations for Pediatric Studies for Drugs and Biological Products.
U.S. Department of Health and Human Services Food and Drug
Administration, Center for Drug Evaluation and Research (CDER), Center
for Biologics Evaluation and Research (CBER), December 2014,
https://www.fda.gov/media/90358/download
[23] Draft guidance for industry: How to comply with the Pediatric
Research Equity Act. Silver Spring, MD: Food and Drug Administration;
2005. [(accessed July 9, 2020)].
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077855.pdf
[24] Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M
and Mayhew S. The COVID-19 vaccine development landscape. Nature Reviews
Drug Discovery 19, 305-306 (2020), doi: 10.1038/d41573-020-00073-5
[25] Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef
SK, Kumar D, Ramakrishnan MA, Malik YS, Singh R, Malik SVS, Singh RK,
Chaicumpa W. Advances in Designing and Developing Vaccines, Drugs, and
Therapies to Counter Ebola Virus. Front Immunol. 2018 Aug 10;9:1803.
doi: 10.3389/fimmu.2018.01803. PMID: 30147687; PMCID: PMC6095993.
[26] Draft landscape of COVID 19 candidate vaccines. World Health
Organization. 18 June 2020. Archived from the original on 14 May 2020.
Updated July 7, 2020 Retrieved 9 July 2020,
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[27] Gomes MF, de la Fuente-Núñez V, Saxena A, Kuesel AC. Protected
to death: systematic exclusion of pregnant women from Ebola virus
disease trials. Reprod Health. 2017 Dec 14;14(Suppl 3):172. doi:
10.1186/s12978-017-0430-2. PMID: 29297366; PMCID: PMC5751665.
[28] Guidance for Industry: Post-approval Pregnancy Safety Studies.
U.S. Department of Health and Human Services Food and Drug
Administration, Center for Drug Evaluation and Research (CDER), Center
for Biologics Evaluation and Research (CBER), May 2019,
https://www.fda.gov/media/124746/download
[29] Institute of Medicine. 2012. Adverse Effects of Vaccines:
Evidence and Causality. Washington, DC: The National Academies Press.
https://doi.org/10.17226/13164.
[30] Check Hayden, E. Vaccines given a clean bill of health. Nature
(2011). https://doi.org/10.1038/news.2011.505
[31] Faucette AN, Pawlitz MD, Pei B, Yao F, Chen K. Immunization of
pregnant women: Future of early infant protection. Hum Vaccin
Immunother. 2015;11(11):2549-55. doi: 10.1080/21645515.2015.1070984.
Epub 2015 Sep 14. PMID: 26366844; PMCID: PMC4685701.
[32] Vivanti, A.J., Vauloup-Fellous, C., Prevot, S. et al.
Transplacental transmission of SARS-CoV-2 infection. Nat Commun 11, 3572
(2020). https://doi.org/10.1038/s41467-020-17436-6.
[33] Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory
syndrome in children in New York State. N Engl J Med 2020;383:347-358.
[34] Callaway, E. (2020c). Coronavirus vaccine trials have delivered
their first results - but their promise is still unclear. Nature 581,
363–364. doi: 10.1038/d41586-020-01092-3
[35] Cristiani L, Mancino E, Matera L, et al. Will children reveal
their secret? The coronavirus dilemma. Eur Respir J. 2020;55(4):2000749.
Published 2020 Apr 23. doi:10.1183/13993003.00749-2020
[36] Park YJ, Choe YJ, Park O, Park SY, Kim YM, Kim J, et al.
Contact tracing during coronavirus disease outbreak, South Korea, 2020.
Emerg Infect Dis. 2020 Oct [date cited].
https://doi.org/10.3201/eid2610.201315, DOI: 10.3201/eid2610.201315
[37] Shiau S, Kuhn L. Antiretroviral treatment in HIV-infected
infants and young children: novel issues raised by the Mississippi baby.
Expert Rev Anti Infect Ther. 2014 Mar;12(3):307-18. doi:
10.1586/14787210.2014.888311. Epub 2014 Feb 9. PMID: 24506199; PMCID:
PMC5389381.
[38] Siemieniuk Reed A C, Lytvyn Lyubov, Mah Ming Jinell, Mullen
Rhonda Marama, Anam Florence, Otieno Teresia et al. Antiretroviral
therapy in pregnant women living with HIV: a clinical practice guideline
BMJ 2017; 358 :j3961.
[39] Coutre L. Cleveland Clinic, Epic develop home monitoring tool
for COVID-19 patients. April 30, 2020. Modern Healthcare.
https://www.modernhealthcare.com/technology/cleveland-clinic-epic-develop-home-monitoring-tool-covid-19-patients.
[40] Boissy A. Getting to Patient-Centered Care in a Post–Covid-19
Digital World: A Proposal for Novel Surveys, Methodology, and Patient
Experience Maturity Assessment. NEJM Catalyst Innovations in Care
Delivery Vol. 1, No. 4: 1-26, 2020.
[41] COVID-19 Prevention Trials Network (COVPN),
https://www.coronaviruspreventionnetwork.org/, last accessed 7/27, 2020.
[42] HIV Vaccine Trials Network (HVTN),
https://www.hvtn.org/en.html, last accessed 7/27, 2020.
[43] HIV Prevention Trials Network (HPTN), https://www.hptn.org/,
last accessed 7/27, 2020.
[44] Infectious Diseases Clinical Research Consortium (IDCRC),
https://www.niaid.nih.gov/research/idcrc, last accessed 7/27, 2020.
[45] Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of
COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen,
China: a retrospective cohort study [published online ahead of print,
2020 Apr 27]. Lancet Infect Dis. 2020; S1473-3099(20)30287-5.
doi:10.1016/S1473-3099(20)30287-5
[46] Lauer, Stephen A., Grantz, Kyra H., Bi, Qifang, Jones, Forrest
K., Zheng, Qulu, Meredith, Hannah R., Azman, Andrew S., Reich, Nicholas
G., Lessler, Justin. The Incubation Period of Coronavirus Disease 2019
(COVID-19) From Publicly Reported Confirmed Cases: Estimation and
Application. Annals of Internal Medicine 2020 172:9, 577-582.
[47] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting
Characteristics, Comorbidities, and Outcomes Among 5700 Patients
Hospitalized With COVID-19 in the New York City Area. JAMA.
2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
[48] Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics
and Outcomes of Children With Coronavirus Disease 2019 (COVID-19)
Infection Admitted to US and Canadian Pediatric Intensive Care Units.
JAMA Pediatr. Published online May 11, 2020.
doi:10.1001/jamapediatrics.2020.1948
[49] CDC COVID-19 Response Team. Coronavirus Disease 2019 in
Children - United States, February 12-April 2, 2020. MMWR Morb Mortal
Wkly Rep 2020; 69:422.
[50] Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and
Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care
Skilled Nursing Facility – King County, Washington, March 2020. MMWR
Morb Mortal Wkly Rep 2020; 69:377–81.
[51] Smith ER, Klein-Schwartz W. Are 1–2 dangerous? Chloroquine and
hydroxychloroquine exposure in toddlers. The Journal of Emergency
Medicine 28(4): 437-443, 2005.
[52] McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of
falciparum and vivax malaria and the safety of antimalarial treatment in
early pregnancy: a population-based study. Lancet Infect Dis.
2012;12(5):388-396. doi:10.1016/S1473-3099(11)70339-5.
[53] Anna-Liisa Laaksonen, Veli Koskiahde & Kale Juva (1974) Dosage
of Antimalarial Drugs for Children with Juvenile Rheumatoid Arthritis
and Systemic Lupus Erythematosus: A Clinical Study with Determination of
Serum Concentrations of Chloroquine and Hydroxychloroquine, Scandinavian
Journal of Rheumatology, 3:2, 103-108, DOI: 10.3109/03009747409115809
[54] Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal
use of hydroxychloroquine is associated with a reduced risk of recurrent
anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal
lupus. Circulation. 2012;126(1):76-82.
doi:10.1161/CIRCULATIONAHA.111.089268.
[55] Bouazza N, Treluyer JM, Foissac F, et al. Favipiravir for
children with Ebola. Lancet. 2015;385(9968):603-604.
doi:10.1016/S0140-6736(15)60232-X.
[56] Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new
medication for the Ebola virus disease pandemic. Disaster Med Public
Health Prep. 2015;9(1):79-81. doi:10.1017/dmp.2014.151.
[57] Rudin C, Burri M, Shen Y, et al. Long-term safety and
effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in
antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J.
2008;27(5):431-437. doi:10.1097 / INF.0b013e3181646d5a.
[58] Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of
HIV-1 infection: a review. Ther Clin Risk Manag. 2008 Oct;4(5):1023-33.
doi: 10.2147/tcrm.s3285. PMID: 19209283; PMCID: PMC2621403.
[59] Simon A, Warszawski J, Kariyawasam D, et al. Association of
Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal
Dysfunction Among Uninfected Infants of HIV-Infected Mothers. JAMA.
2011;306(1):70–78. doi:10.1001/jama.2011.915
[60] Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV,
Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic
Syndr. 2009;51(4):456-461. doi:10.1097/QAI.0b013e3181a2813f
[61] Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon
alfa-2b plus ribavirin treatment in children and adolescents with
chronic hepatitis C. Hepatology. 2005;41(5):1013-1018.
doi:10.1002/hep.20661
[62] Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall
CB, McWilliams BC, Lauer BA. Early ribavirin treatment of respiratory
syncytial viral infection in high-risk children. Journal of Pediatrics
(1990) 117(5): 792-798.
[63] American Academy of Pediatrics Committee on Infectious
Diseases: Use of ribavirin in the treatment of respiratory syncytial
virus infection. Pediatrics. 1993;92(3):501-504.
[64] Schlossberg D, Samuel R. YOMESAN (Niclosamide) in “Antibiotics
Manual: A Guide to Commonly Used Antimicrobials, Second Edition” (2017)
Wiley Online Library, https://doi.org/10.1002/9781119220787.ch199, p
432.
[65] Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on
morbidity and mortality in Zambian children with cryptosporidiosis: a
randomised controlled trial. Lancet. 2002;360(9343):1375-1380.
doi:10.1016/S0140-6736(02)11401-2.
[66] Asami T, Tomisawa S, Uchiyama M. Effect of oral camostat
mesilate on hematuria and/or proteinuria in children. Pediatr Nephrol.
2004;19(3):313-316. doi:10.1007/s00467-003-1377-9.
[67] Svenningsen P, Andersen H, Nielsen LH, Jensen BL. Urinary
serine proteases and activation of ENaC in kidney–implications for
physiological renal salt handling and hypertensive disorders with
albuminuria. Pflugers Arch. 2015;467(3):531-542.
doi:10.1007/s00424-014-1661-5.
[68] Lee, Sang & Cho, Heeyeon. (2014). The Use of Nafamostat
Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy
for Children with a High Risk of Bleeding. Journal of the Korean Society
of Pediatric Nephrology. 18. 98. 10.3339/jkspn.2014.18.2.98.
[69] Hara T, Kanasaki H, Oride A, Ishihara T, Kyo S. A Case of
Idiopathic Acute Pancreatitis in the First Trimester of Pregnancy. Case
Rep Obstet Gynecol. 2015; 2015:469527. doi: 10.1155/2015/469527. Epub
2015 Dec 30. PMID: 26843995; PMCID: PMC4710924.
[70] Wu KH, Weng T, Wu HP, Peng CT, Sheu JN, Chao YH. Effective
treatment of severe BK virus-associated hemorrhagic cystitis with
leflunomide in children after hematopoietic stem cell transplantation: a
pilot study. Pediatr Infect Dis J. 2014;33(11):1193-1195.
doi:10.1097/INF.0000000000000407
[71] Habal FM, Huang VW. Review article: a decision-making algorithm
for the management of pregnancy in the inflammatory bowel disease
patient. Aliment Pharmacol Ther 2012; 35: 501–515.
[72] Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in
women who have taken leflunomide during pregnancy. Arthritis Rheum.
2010;62(5):1494-1503. doi:10.1002/art.27358.
[73] Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue
reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or
ritonavir for pretreated children infected with human immunodeficiency
virus type 1. Clin Infect Dis. 2002;34(7):991-1001. doi:10.1086/338814.
[74] Aronson JK. Teicoplanin, In “Meyler’s Side Effects of Drugs:
The International Encyclopedia of Adverse Drug Reactions and
Interactions,” 2016, Elsevier Publishers, p 714-720.
[75] Giardina AC, Ehlers KH, Morrison JB, Engle MA. Serum digitoxin
concentrations in infants and children. Circulation. 1975;51(4):713-717.
doi:10.1161/01.cir.51.4.713.
[76] Okita, G.T., Plotz, E.J., Davis, M.E.: Placental transfer of
radioactive digitoxin in pregnant women and its fetal distribution.
Circulation 9, 376–380 (1956).
[77] Neely M, Kovacs A. Managing treatment-experienced pediatric and
adolescent HIV patients: role of darunavir. Ther Clin Risk Manag.
2009;5(3):595-615. doi:10.2147/tcrm.s4595.
[78] Zorrilla CD, Wright R, Oisyemi OO, et al. Total and unbound
darunavir pharmacokinetics in pregnant women infected with HIV-1:
results of a study of darunvair/ritonavir 600/100 mg administered twice
daily. HIV Med. 2014;15(1):50–56.
[79] Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term
azithromycin in children with cystic fibrosis: a randomised,
placebo-controlled crossover trial. Lancet. 2002;360(9338):978-984.
doi:10.1016/s0140-6736(02)11081-6.
[80] Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A
randomized controlled trial comparing amoxicillin and azithromycin for
the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol
2001; 184:1352–6.
[81] del Mar Saez-De-Ocariz M., McKinster C.D., Orozco-Covarrubias
L., Tamayo-Sánchez L., Ruiz-Maldonaldo R. (2002) Treatment of 18
children with scabies or cutaneous larva migrans using ivermectin. Clin.
Exp. Dermatol. 27, 264–267.
[82] Richard-Lenoble D, Chandeniera J, Gaxotte P. Ivermectin and
filariasis. Fundamental & Clinical Pharmacology 17 (2003) 199–203.
[84] Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A
critical review of pharmacology, pre-clinical and clinical studies.
Diabetes Metab Syndr. 2020 May 12;14(4):641-648. doi:
10.1016/j.dsx.2020.05.018. Epub ahead of print. PMID: 32428865; PMCID:
PMC7214279.
[83] FDA emergency use authorization for remdisivir.
https://www.fda.gov/media/137564/download (Accessed May 5, 2020)
[85] Wilson K.C., Chotirmall S.H., Bai C., Rello J. COVID-19:
interim guidance on management pending empirical evidence.
https://www.thoracic.org/covid/covid-19-guidance.pdf April 3. 2020.
[86] Webb NJ, Lam C, Loeys T, et al. Randomized, double-blind,
controlled study of losartan in children with proteinuria. Clin J Am Soc
Nephrol. 2010;5(3):417-424. doi:10.2215/CJN.06620909.
[87] Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal
toxic effects. Lancet. 2001;357(9253):363.
doi:10.1016/S0140-6736(00)03648-5.
[88] Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M.
Clinical study of tocilizumab in children with systemic-onset juvenile
idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28(3):231-238.
doi:10.1385/CRIAI:28:3:231.
[89] Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in
pregnancy: Analysis of a global safety database including data from
clinical trials and post-marketing data. Semin Arthritis Rheum.
2016;46(2):238-245. doi:10.1016/j.semarthrit.2016.05.004.
[90] Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa
therapy for chronic hepatitis B in children: a multinational randomized
controlled trial. Gastroenterology. 1998;114(5):988-995.
doi:10.1016/s0016-5085(98)70318-x.
[91] Séror J, Sentilhes L, Lefebvre-Lacoeuille C, Marpeau L.
Interferon-alpha for treatment of essential thrombocythemia during
pregnancy: case report and review of the literature. Fetal Diagn Ther.
2009;25(1):136-140. doi:10.1159/000207555.
[92] Smith RL. Pediatric psoriasis treated with apremilast. JAAD
Case Rep. 2016 Feb 27;2(1):89-91. doi: 10.1016/j.jdcr.2015.12.005. PMID:
27051839; PMCID: PMC4809471.
[93] Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and
safety of apremilast in pediatric patients with moderate to severe
plaque psoriasis: Results from a phase 2 open-label study. J Am Acad
Dermatol. 2020;82(2):389-397. doi:10.1016/j.jaad.2019.08.019